Trial Profile
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Post acute COVID 19 syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms REVERSE-LC; REVERSE-Long COVID
- 22 Mar 2024 Planned initiation date changed from 4 Mar 2024 to 15 Jun 2024.
- 16 Jan 2024 Planned number of patients changed from 500 to 550, Phase of this study has been changed to Phase 3.
- 16 Jan 2024 Planned initiation date changed from 1 Jan 2024 to 4 Mar 2024.